Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate

Wide variability in apparent half-lives of flupentixol decanoate has been reported (5.3-112.6 days), owing to uneven release of the ester from the oil.

“However, wide variability in apparent half-lives has been reported (5.3–112.6 days), owing to uneven release of the ester from the oil.”

Flupentixol LAI is formulated with the cis(Z)-flupenthixol isomer (the active enantiomer) using a decanoate ester in the coconut-derived oil vehicle Viscoleo.

“The LAI preparation is formulated with cis(Z)-flupenthixol isomer (the active enantiomer) using a decanoate ester in the coconut-derived oil vehicle, Viscoleo [44].”

The depot properties of flupentixol decanoate depend on the slow release of the ester from the oil vehicle.

“the depot properties depend on the slow release of the ester from the oil vehicle [44]”

Peak plasma concentrations of flupentixol decanoate are achieved 4-10 days after injection, indicating relatively slow absorption compared with the tmax of oral flupentixol (4 h).

“Peak plasma concentrations of flupentixol decanoate are achieved 4–10 days after injection, indicating a relatively slow absorption compared with the tmax of oral flupentixol (4 h) [44].”

The mean apparent half-life of flupentixol decanoate was estimated at 17.3 days, based on steady-state concentration data obtained at days 14, 21, and 28.

“The mean apparent half-life was estimated at 17.3 days, based on concentration data at steady state obtained at days 14, 21, and 28 [44].”

Oral flupentixol 10 mg per day was estimated to be equivalent to intramuscular flupentixol decanoate 40 mg every 2 weeks.

“Oral flupentixol 10 mg per day was estimated to be equivalent to intramuscular flupentixol decanoate 40 mg every 2 weeks [44].”